- Home
- TMP vs GHRS Comparison
TMP vs GHRS Comparison
Compare TMP & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMP | GHRS |
|---|---|---|
| Founded | 1836 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TMP | GHRS |
|---|---|---|
| Price | $75.92 | $13.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $74.00 | $41.38 |
| AVG Volume (30 Days) | 46.0K | ★ 203.2K |
| Earning Date | 04-24-2026 | 03-05-2026 |
| Dividend Yield | ★ 3.63% | N/A |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 11.24 | N/A |
| Revenue | ★ $75,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.94 | N/A |
| P/E Ratio | $6.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.16 | $7.98 |
| 52 Week High | $86.95 | $19.51 |
Technical Indicators
Market Signals| Indicator | TMP | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 36.79 |
| Support Level | $72.14 | $12.14 |
| Resistance Level | $77.33 | $14.80 |
| Average True Range (ATR) | 1.97 | 0.84 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 63.80 | 12.05 |
Price Performance
Historical ComparisonAbout TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.